Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Doxorubicin and Ifosfamide as First-line Treatment for Advanced Soft Tissue Sarcoma
NCT07243626Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in soft tissue sarcoma (STS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Sep 2024; status: recruiting.
02
Drugs
envafolimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07243626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07243626.